{"blog": [], "keywords": [{"value": "Gilead Sciences Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Company Reports", "name": "subject", "rank": "2", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Hepatitis", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Harvoni (Drug)", "name": "subject", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/29/business/discounts-on-hepatitis-c-drug-dent-gileads-earnings.html", "document_type": "article", "byline": {"person": [], "original": "By THE ASSOCIATED PRESS", "organization": "THE ASSOCIATED PRESS"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "371", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The maker of Harvoni, a treatment for hepatitis C, said sales of the drug fell 15 percent in the first quarter.", "pub_date": "2016-04-29T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Discounts on Hepatitis C Drug Dent Gilead\u2019s Earnings", "main": "Discounts on Hepatitis C Drug Dent Gilead\u2019s Earnings"}, "print_page": "7", "snippet": "The maker of Harvoni, a treatment for hepatitis C, said sales of the drug fell 15 percent in the first quarter.", "_id": "5722a86e38f0d83c40473c01", "slideshow_credits": null, "abstract": "Gilead Science reports first-quarter profit of $2.53 a share, down 17 percent from $2.76 a share in year-ago quarter; revenue was $7.79 billion; discounts and rebates on hepatitis C drugs impede profit, with sales of Harvoni down 15 percent."}